Bi-Sialidase

Press Release

Bi-Sialidase

Bi-Sialidase

Palleon’s lead program, Bi-Sialidase E-602, is a first-in-class molecule that addresses T cell exhaustion in refractory cancer patients. The molecule enzymatically degrades T cell surface cis-sialoglycans, which contribute to T cell exhaustion by inhibiting immune activating receptors. Palleon’s data suggests that T cell exhaustion can be reversed by this novel cell surface glycan-editing strategy.